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 1 
Abstract : words 243 1 
 2 
Proteases and Protease-Activated Receptors (PARs) are major mediators involved in irritable 3 
bowel syndrome (IBS). Our objectives were to decipher the expression and functionality 4 
(calcium signaling) of PARs in human dorsal root ganglia (DRG) neurons, and to define 5 
mechanisms involved in human sensory neuron signaling by IBS patient mediators. 6 
Human thoracic DRG were obtained from the national disease resource interchange. 7 
Expression of PAR1, PAR2 and PAR4 was assessed by immunohistochemistry and RT-qPCR in 8 
whole DRG or in primary cultures of isolated neurons. Calcium signaling in response to PAR 9 
agonist peptides (PAR-AP), their inactive peptides (PAR-IP), thrombin (10u/ml), supernatants 10 
from colonic biopsies of IBS patients or healthy controls (HC), with or without PAR1 or PAR4 11 
antagonist were studied in cultured human DRG neurons.  12 
PAR1, PAR2 and PAR4 were all expressed in human DRG, respectively in 20%, 40% and 40% of 13 
the sensory neurons. PAR1-AP increased intracellular calcium concentration in a dose-14 
dependent manner. This increase was inhibited by PAR1 antagonism. In contrast, PAR2-AP, 15 
PAR4-AP and PAR-IP did not cause calcium mobilization. PAR1-AP-induced calcium flux was 16 
significantly reduced by pre-incubation with PAR4-AP, but not with PAR2-AP. Thrombin 17 
increased calcium flux, which was inhibited by a PAR1 antagonist and increased by a PAR4 18 
antagonist. Supernatants from colonic biopsies of IBS patients induced calcium flux in human 19 
sensory neurons compared to HC, this induction was reversed by a PAR1 antagonist. 20 
Taken together, our results highlight that PAR1 antagonism should be investigated as a new 21 
therapeutic target for IBS symptoms.  22 
 23 
Keywords: Proteases; PARs; Protease-Activated Receptors; Visceral pain; Inflammation; 24 
Irritable Bowel Syndrome; Visceral hypersensivity; Thrombin; Human dorsal root ganglia 25 
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 2 
Introduction 27 
Irritable Bowel Syndrome (IBS) affects 11 to 20% of the Western population with a 28 
higher prevalence in women [14; 31]. IBS associates abdominal pain, diarrhea (IBS-D), 29 
constipation (IBS-C) or both (IBS-A, for alternate) [30]. Although IBS is a functional 30 
gastrointestinal disorder, not associated with gross structural or biochemical abnormalities 31 
[23], several recent studies indicate the presence of meaningful micro-organic changes [7].  32 
One of the emerging ideas to explain the visceral pain associated with IBS is that sensory 33 
neurons innervating the colon are hyperexcitable in these patients [10; 11; 13]. However, 34 
because of the difficulties associated with human sensory neuron cultures, it has been 35 
difficult to evaluate the relevance of identified mediators in the context of human pathology. 36 
Among the molecular targets explored to decipher neuronal hyperexcitability in IBS, 37 
several studies showed that proteases released by colonic biopsies of IBS patients were able 38 
to activate mouse and rat intestinal neurons in vitro and to induce somatic and visceral 39 
hypersensitivity in vivo [9; 13; 17; 38; 47]. Proteases are known to signal to mouse or rat 40 
sensory neurons through the activation of Protease-Activated Receptors (PARs) [19; 46; 53; 41 
55], a family of G protein-coupled receptors that includes 4 members: PAR1, PAR2, PAR3 and 42 
PAR4 [40]. Only PAR1, PAR2 and PAR4 seem to be able to signal through calcium mobilization 43 
and to exert a role in nociception and pain (PAR3 has been considered more as a co-factor 44 
for other PAR activation[35] so far). PAR1, 2 and 4 are activated by the proteolytic cleavage of 45 
their N-terminal domain, which reveals a tethered ligand that binds and activates the 46 
receptors.  The role of PARs in visceral inflammation and pain has been well studied in 47 
animal models[49; 50]. Both PAR1 and PAR2 agonists induce calcium mobilization in rodent 48 
sensory neurons[17; 21]. PAR2 agonists induce pain in somatic and visceral models [51; 53], 49 
while PAR1 and PAR4 agonists attenuate nociception and pain symptoms in rodents [4-6; 32]. 50 
In mouse sensory neurons, the calcium mobilization induced by supernatants from colonic 51 
biopsies of IBS patients is dependent on supernatant’s proteolytic activity and on PAR2 52 
expression in mouse primary afferents [17]. In contrast, PAR4 activation inhibits PAR2-53 
induced calcium mobilization and intrinsic excitability of colonic dorsal root ganglia (DRG) 54 
neurons, as well as overall pain [5; 6; 28]. However, in the context of human nociception and 55 
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 3 
Proteases show different specificity for the different PARs[52]. For instance, thrombin 57 
can activate PAR1, PAR3, PAR4 and to a lower extend PAR2, trypsin can activate PAR2, PAR3 58 
and PAR4 and at high concentrations PAR1 [25; 33; 42]. In the context of IBS, tryptase and 59 
trypsin-3 are up-regulated, and are considered as possible endogenous agonists for PARs[9; 60 
43].  61 
Our study aimed at deciphering PAR signaling in human sensory neurons, 62 
determining whether proteases and PARs could play a role in human sensory neuron biology 63 
and nociceptive mechanisms. Further, we investigated human sensory neuron responses to 64 
IBS mediators in cultured human DRG neurons. Although not only neurons projecting from 65 
the digestive tract are present in our cultures, the present study could give insights in the 66 
response of human primary afferents to mediators present in IBS patient tissues. 67 
 68 
Methods  69 
Chemicals 70 
Each agonist and inactive peptides of PARs, respectively PAR-AP and PAR-IP, where 71 
purchased from Genscript (France):  PAR1-AP (TFFLR), PAR2-AP (SLIGKV), PAR4-AP (GYPGQV), 72 
PAR1-IP (RLLFT), PAR2-AP (LRGILS) and PAR4-AP (YAPGQV). Thrombin, PAR1-antagonist 73 
(SCH79797), PAR2 antagonist (GB83) and PAR4-antagonist (ML354) were obtained from 74 
Tocris (Denver, USA). 75 
 76 
Patient biopsies and supernatant collection 77 
Colon biopsy samples from 24 patients with IBS (8 IBS-D, 8 IBS-C, 8 IBS-A) and 5 healthy 78 
controls, HCs) undergoing colorectal cancer screening were collected during colonoscopy at 79 
the Department of Medical and Surgical Sciences of the University of Bologna, Italy 80 
(Supplementary Table 1, available online at http://links.lww.com/PAIN/A553). Rome III 81 
criteria were used for the diagnosis of IBS patients. Additional exclusion criteria were major 82 
abdominal surgery, celiac disease, asthma, allergic disorders, anti-inflammatory treatments, 83 
organic syndrome. Symptoms as bloating, pain and bowel habit changes in the last 12 84 
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 4 
Supernatants from colonic biopsies were obtained following a previously validated and 87 
published method [8], with few modifications. Briefly, after removal, biopsies were 88 
immersed in plastic tubes containing 1 ml of Hepes-Krebs solution. After weighing the 89 
biopsies, supernatant volume was adjusted to incubate 15 mg of biopsies in 1 ml of buffer. 90 
Incubation was carried out in oxygenation at 37°C for 25 min. Samples were centrifuged at 91 
200g for 10 min and supernatant collected and stored at –20°C until the assay. 92 
 93 
Human Dorsal Root Ganglia Neurons Isolation 94 
Experiments were conducted under the Institutional Review Board numbers IRB00003888, 95 
FWA00005831.  Human DRG (thoracic position 11 and 12) were collected in Dulbecco's 96 
Modified Eagle's medium by the National Disease Resource Interchange (NDRI). Twenty DRG 97 
were obtained from 10 post-mortem donors (21-60 years old, 10 hours maximum post-98 
mortem) with the following exclusion criteria: chemotherapy, drug abuse, infectious disease, 99 
neurodegenerative diseases and opioid medications. None of the donors had a reported 100 
history of colitis or inflammatory bowel disease, but no information was provided about 101 
possible IBS. DRG were cut in small pieces, rinsed in Hank's balanced salt solution (HBSS; 102 
Thermo Fisher, Villebon-sur-Yvette, France) and digested in L-Cystein (pH 7.4, Sigma Aldrich, 103 
Missouri, USA), Papain (27 µg/ml, Sigma Aldrich, Missouri, USA) for 20 minutes at 37°C, 104 
rinsed 2 minutes in Leibovitz's L15 Medium (Thermo Fisher Scientific, Waltham, 105 
Massachusetts, USA) containing 10 % of FBS. A second enzymatic dissociation was 106 
performed in 4 mg/ml dispase II (Sigma Aldrich, Missouri, USA), and 1 mg/ml collagenase 107 
(collagenase (type IV, Serlabo Technologies, France) for 15 minutes at 37°C, followed by 108 
mechanical dissociation. This step was repeated until complete dissociation of the DRG up to 109 
4 times. Finally, neurons were plated in 8-wells Nunc™ Lab-Tek™ II CC2™ chamber slide 110 
system (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and cultured for 7 days in 111 
complete Neurobasal-A medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) 112 
containing penicillin (100 µg/ml), streptomycin (100µg/ml), B27 (1X, Thermo Fisher 113 
Scientific, Waltham, Massachusetts, USA), L-glutamine (1X, Thermo Fisher Scientific, 114 
Waltham, Massachusetts, USA), and inhibitors of mitosis (Cytosine-B-arabinofuranoside 115 
1.5µM, F-Uridine 10µM, Uridine, 10µM, Sigma Aldrich, Missouri, USA). Cytosine-B-116 
arabinofuranoside was removed after 3 days of culture and the medium was changed every 117 
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 5 
For RT-qPCR and single-cell PCR studies, human thoracolumbar DRG (T9-L1) were acquired 119 
from five (three females, two males) human adult organ donors (22.2 ± 2.08 years of age) 120 
during the removal of vital organs for transplantation. The harvested intact DRG were kept 121 
for quantitative-reverse-transcription-PCR (RT-qPCR) mRNA expression studies, while 122 
additional DRG were dissociated to allow individual DRG neurons to be isolated and studied 123 
with single-cell-reverse-transcription-PCR (RT-PCR).  124 
 125 
Calcium imaging of human sensory neurons  126 
After washing with HBSS, cultured neurons were incubated for 1 hour (30 min at 37°C 127 
followed by 30 min at room temperature) in solution containing fluo-4 acetoxymethyl (AM) 128 
1mM (Thermo Fisher Scientific, Waltham, Massachusetts, USA) reconstituted in 0.01% 129 
pluronic F-127 and 0.7% DMSO (Sigma Aldrich, Missouri, USA). The fluorescence was 130 
measured at 460-490 nm excitation and 515 nm emission in each well. Neurons were 131 
imaged using an inverted microscope (Zeiss, 10x-objective) and a CCD camera (Zeiss). 132 
Acquisition parameters were kept constant within each experiment. A kinetic of 80 133 
recordings (one per second) was performed. From 0 to 5-sec basal fluorescence was 134 
determined, from 6 to 60-sec, neurons were exposed to the different molecules studied and 135 
finally to a KCl solution (50 mM), in order to discriminate neurons from glial cells. Neurons 136 
were identified by Image J software and variations in the fluorescence intensity of each 137 
neuron was measured. Results were expressed as ∆F/F, representing the fluorescence 138 
intensity ratio between the highest measure during the 6 to 60 seconds  period, and baseline 139 
measure. 140 
 141 
In a first set of experiments, neurons were treated with individual PAR agonist peptides: 142 
PAR1-AP (1, 10, 50 or 100 µM), PAR2-AP (100 µM), PAR4-AP (100 µM) or neurons were pre-143 
incubated for 5 minutes with PAR2-AP (100 µM) or PAR4-AP (100 µM), before being exposed 144 
to PAR1-AP (100 µM). For these experiments, the inactive peptides (PAR-IP, 100 µM) and 145 
vehicle (HBSS) were used as control. In a second set of experiments, neurons were pre-146 
incubated for 5 minutes with antagonist of PAR1 (SCH79797, 10 µM) or its vehicle (HBSS, 147 
0.01% DMSO) and treated with PAR1-AP (100 µM). In a third set of experiments, neurons 148 
were pretreated 5 minutes with the PAR1antagonist (SCH79797, 10 µM), the PAR4 antagonist 149 





Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
 6 
U/ml). In a last set of experiments, neurons were pretreated 5 minutes with the PAR1 151 
antagonist (SCH79797, 10µM) or vehicle, before being exposed to supernatants from colonic 152 
biopsies of IBS-D, IBS-C, IBS-A patients or HCs.  153 
 154 
Immunofluorescence in human Dorsal Root Ganglia 155 
Experiments were conducted under the Institutional Review Board numbers IRB00003888, 156 
and FWA00005831. Three Human DRG T11 and 3 DRG T12 (thoracic position 11 and 12) 157 
were cryoprotected in Tissue-Tek® optimum cutting temperature compound (Sakura 158 
Finetek, Netherlands) after their collection by the NDRI. Cryoprotected DRG were cut into 35 159 
µm sections in a cryostat (Leica CM1950; Nanterre, France) and mounted on Superfrost 160 
slides (Thermo Fisher Scientific, Villebonne-sur-Yvette, France). Cultured DRG neurons were 161 
fixed with paraformaldehyde 4% during 20 min. Both slides and cultures were washed in 162 
Phosphate Buffered Saline (PBS), 0.5% Triton X-100, and 1% Bovine Serum Albumin solution 163 
(BSA, Sigma Aldrich, Missouri, USA) and were incubated overnight at 4°C with primary 164 
antibodies diluted at 1:100 for tissues and 1:500 for cultures and directed against PGP9.5, 165 
PAR1, PAR4 (respectively, AB86808, AB111976, AB70400, Abcam, Cambridge, England) and 166 
PAR2 (LSB2321, LifeSpan, Seattle, USA). After washing in PBS, slices or cultures were 167 
incubated with the appropriate secondary antibody conjugated to Alexa Fluor 488 or Alexa 168 
Fluor 555, they were washed, and mounted with ProLong Gold reagent containing 40,6-169 
diamidino-2-phenylindole (DAPI, Molecular Probes). Controls for the specificity of the 170 
antibodies include incubation in the absence of secondary antibody, incubation in the 171 
presence of immunizing peptides and the use of PAR-deficient tissues or cells (not shown). 172 
Images were acquired using Zeiss LSM-710 confocal microscopes (Carl Zeiss MicroImaging, 173 
Jena, Germany) with 10x objective in the inverted configuration [20]. Quantification of 174 
labelling was determined using Image J software.   175 
 176 
Quantitative-reverse-transcription-PCR (RT-qPCR):       177 
RNA was extracted from either whole human DRG or single human DRG neurons using RNA-178 
isolation kits (PureLink™ and Cells-to-CT™; Ambion). RT-qPCR was performed using human-179 
specific Taqman primers for PAR1, PAR2, PAR4 and GAPDH (Hs00169258_m1, 180 
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 7 
cycle threshold method was used to quantify the abundance of target transcripts to 182 
reference genes.  183 
 184 
Single cell PCR:                      185 
26 single dissociated DRG neurons were picked using a micromanipulator at 40x 186 
magnification. Cells were under a continuous slow flow of sterile and RNA/DNAse free PBS to 187 
reduce contamination. After a cell was picked, the glass capillary was broken into a tube 188 
containing 10ul of Lysis buffer and DNAse (TaqMan® Gene Expression Cells-to-CT™ Kit; 189 
Ambion). The whole content was used for cDNA synthesis (SuperScript® VILO™ cDNA 190 
Synthesis Kit, Thermo Fisher) and PAR1, PAR2, PAR4 expression was measured using 191 
Taqman™ RT-qPCR for 50 cycles. For every coverslip, a bath control was taken and analyzed 192 
together with samples. TUBB3 (Hs00964962_g1) expression served as positive control. One 193 
cell was excluded because no TUBB3 expression was present. Twenty-six cells were used to 194 
calculate frequency of presence of PAR1, PAR2 and PAR4.  195 
 196 
Statistical Analysis 197 
Data are presented as means ± standard error of the mean (SEM). Analyses were performed 198 
using GraphPad Prism 5.0 software (GraphPad, San Diego, CA). Comparisons between-199 
groups were performed by Mann-Whitney test or Wilcoxon matched pairs test. Multiple 200 
comparisons within groups were performed by Kruskal-Wallis test, followed by Dunn’s post-201 
test. Statistical significance was accepted at P < 0.05. 202 
 203 
Study approval 204 
The collection of biopsies from colonic patients was approved by the local Ethic Committee 205 
(64/2004/O/Sper and EM14/2006/O) and conducted in accordance with the Declaration of 206 
Helsinki. IBS patients and HCs gave their written and informed consent. Fixed and fresh 207 
human DRG were collected with the NDRI (reference: DCEN1 001), all human DRG trials were 208 
conducted following the opinion number 14-164 of the institutional review board 209 
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 8 
Results 213 
-PAR expression in human DRG neurons- 214 
In whole human DRG, PAR mRNA expression was assessed by RT-qPCR analysis. The 215 
relative mRNA abundance of PAR2 was the highest followed by PAR4 and PAR1 (Figure 1a). 216 
Then, to determine if PARs were expressed in neurons at the protein level, the percentage of 217 
neurons, identified by Pgp9.5 immunostaining and expressing each PAR was studied (Figure 218 
1b). PAR1, PAR2 and PAR4 were respectively expressed in 20%, 40% and 40% of neurons 219 
(Figure 1c). The percentage of PAR-positive neurons was expressed in function of the 220 
diameter of neurons. PAR1 was preferentially expressed in 30 to 50 µM diameter neurons, 221 
PAR2 in neurons with a diameter < 30 µM and PAR4 in 30 to 50 µM diameter neurons (Figure 222 
1d).  223 
PAR expression was then assessed in cultured human DRG neurons. Cultures were 224 
90% pure for Pgp9.5 neuronal marker staining (Supplementary Figure 1, available online at 225 
http://links.lww.com/PAIN/A553). Single cell PCR experiments showed that PAR1, PAR2 and 226 
PAR4 mRNA were respectively expressed in 20%, 25% and 17% of neurons (Figure 2a left 227 
panel). We found that 75% of PAR1 expressing neurons also expressed PAR2, 100% of the 228 
PAR4 expressing neurons also expressed PAR2, whilst 25% of the PAR1 expressing neurons 229 
also expressed PAR4 (Figure 2a right panel). PAR1, PAR2 and PAR4 were respectively 230 
expressed at the protein level in 35%, 36% and 27% of neurons (Figure 2b and 2c). These 231 
results demonstrate that human DRG neurons in culture continue to express PAR1, PAR2 and 232 
PAR4 and no major or significant difference was observed between the level of expression of 233 
PARs in whole DRGs and in cultured DRGs.  234 
-Effects of PAR agonists on calcium mobilization in human DRG neurons-  235 
Calcium flux in response to specific synthetic agonist peptides of each PAR was 236 
quantified in human sensory neuron cultures. Only PAR1-activating peptide (PAR1-AP, 100-237 
µM) evoked a transient increase in [Ca2+]i that was maximal after 20 seconds and declined 238 
to baseline afterwards, compared to PAR2-AP and PAR4-AP (Figure 3a). This activation was 239 
characterized by an increased percentage of responding neurons (Figure 3b) and increased 240 
amplitude (∆F/F) of response (Figure 3c), compared to its inactive peptide (PAR1-IP, 100-241 
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 9 
by a PAR1 antagonist (SCH79797, 10-µM) (Figure 3d). Agonists and inactive peptides of PAR2 243 
and PAR4 (all at 100-µM) had no significant effect on calcium signaling in human cultured 244 
DRG (Figure 3a, 3b and 3c).   245 
As PAR2 and PAR4 agonist peptides did not induce calcium mobilization, we tested 246 
their potential inhibitory role on PAR1-AP-induced calcium flux. Human DRG were pretreated 247 
with PAR2-AP or PAR4-AP and, 5 min after later, PAR1-AP was added (all agonists at 100 µM). 248 
The transient increase in [Ca2+]i induced by PAR1-AP was decreased by PAR4-AP but not by 249 
PAR2-AP pretreatment (Figure 3e). Both the percentage of responding neurons and the 250 
amplitude of response induced by a PAR1 agonist were significantly reduced by PAR4-AP, but 251 
not by PAR2-AP pretreatment (Figure 3f and 3g).  252 
- Thrombin signals to human DRG neurons  253 
Considering the calcium mobilization responses of human sensory DRG neurons to 254 
PAR1 and PAR4 peptidic agonists, we investigated the effects of thrombin (10U/ml), a known 255 
endogenous activator of both PAR1 and PAR4. The average amplitude of thrombin-induced 256 
calcium response in human DRG neurons was significantly increased compared to vehicle 257 
(Figure 4a). Pre-treatment with a PAR1 antagonist (SCH79797, 10 µM) significantly reduced 258 
the effects of thrombin on the percentage of responding neurons. Pre-treatment with a PAR4 259 
antagonist (ML354, 10 µM) had no effect on this parameter (Figure 4b). Considering only 260 
neurons that responded to thrombin by mobilizing calcium (23% or all neurons), the 261 
amplitude of their response to thrombin was significantly increased in the presence of PAR4 262 
antagonist, but was not modified by a PAR1 antagonist (Figure 4c). These results 263 
demonstrated that in human DRG neurons, thrombin activates both PAR1 and PAR4, exerting 264 
opposite effects in terms of calcium mobilization.  265 
-IBS patient mediators mobilize calcium in human DRG neurons through a PAR1-dependent 266 
mechanism- 267 
IBS supernatants, but not supernatants from healthy control, evoked a transient 268 
increase in [Ca2+]i that was maximal after 30 seconds and declined to baseline afterwards 269 
(Figure 5a). Supernatants from colonic biopsies of IBS patients significantly increased the 270 
amplitude of the calcium flux response and the percentage of responding neurons compared 271 
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 10
neurons, nor the amplitude of the response of human neurons to IBS patient tissue biopsy 273 
supernatants correlated with abdominal pain scores or abdominal frequency scores 274 
(supplementary Figure 2, available online at http://links.lww.com/PAIN/A553).  When 275 
considered by subgroups, only supernatants from IBS-A patients induced a significant 276 
increase in the number of responding neurons (Supplementary Figure 3, available online at 277 
http://links.lww.com/PAIN/A553). PAR1 antagonist (SCH79797, 10 µM) pretreatment of 278 
human sensory neurons decreased the transient increase in [Ca2+]i induced by IBS 279 
supernatants (Figure 5d). The antagonist significantly reduced both the percentage of 280 
responding neurons to IBS supernatants (all IBS subgroups together) and the amplitude of 281 
their response (Figure 5e and 5f).  282 
 283 
Discussion  284 
Since their discovery in rodent neurons [46; 53], PARs have been considered as new 285 
important therapeutic targets for the treatment of pain. A number of in vivo and in vitro 286 
studies have confirmed this potential role for PARs, particularly in the context of visceral 287 
pain and hypersensitivity [19; 49; 51; 52]. However, the relevance of considering PAR 288 
signaling as an important pathway for human pain has not been thoughtfully addressed thus 289 
far. Indeed, only one study performed in human subjects refers to a possible role for PAR2 in 290 
pruritus[45], but no study has investigated the expression and functionality of PARs in 291 
human DRG neurons. Here, we provide evidences that PAR1, PAR2 and PAR4 are all expressed 292 
in human sensory neurons.  Furthermore, we showed that in culture, the expression of PARs 293 
is generally conserved and that the culture conditions we have defined for human DRG 294 
neurons can be used to investigate the functionality of human sensory neurons. Although 295 
our results provide new insights on human primary afferent signaling, the link to activation 296 
of pain pathways would clearly require further experiments.  297 
Previous studies performed in rodent primary afferents have demonstrated the 298 
expression of the three functional PARs: PAR1, PAR2 and PAR4 [21; 46]. We confirmed here 299 
that those three receptors are also expressed in human primary afferent neurons both in cell 300 
bodies of whole DRG neurons and in cultures. In rodent sensory neurons, both PAR1 and 301 





Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
 11
mobilize calcium, but decreased pro-nociceptive mediator-induced calcium signaling [6; 28]. 303 
In human sensory neurons, we demonstrated that only PAR1 agonist induced calcium 304 
mobilization. Like in rodents, in human DRG neurons, PAR4 was not able to mobilize calcium, 305 
but decreased calcium mobilization induced by other agonists. Taken together, our results 306 
clearly demonstrated that both PAR1 and PAR4 were present and functional in human 307 
primary afferents, where they exerted opposing effects. The PAR peptide agonists used in 308 
the present study have been well characterized for their selectivity [26; 27].  The doses that 309 
were used for these peptide agonists in the present study are considered to be highly 310 
selective for their targeted receptors in cell culture assays. Therefore, we can reasonably 311 
think that the results obtained are truly representative of PAR selective activation.  Indeed, 312 
this was confirmed for PAR1 activation by incubation in the presence of the PAR1 antagonist. 313 
At the concentrations used, both SCH79797 and ML354 antagonists were considered 314 
selective for inhibition of PAR1 and PAR4 respectively, compared to the inhibition of other 315 
PARs [1; 57]. However, PAR1-independent effects have also been described for the 316 
SCH79797 compound [22], and one cannot rule out that the effects of this antagonist alone 317 
cannot be due to MAPK inhibition as it has been shown in cell lines at similar concentrations 318 
[22]. The PAR4 antagonist ML354 is potent only at micro-molar ranges, showing a reasonable 319 
selectivity for PAR4, but one cannot rule out at this concentration off-target binding for this 320 
antagonist [57].  321 
Although DRG cultures were 90% pure for neurons, some glial cells or other 322 
supporting cells might still be present in our culture conditions. PARs are known to be 323 
expressed and functional in glial cells and to some extent, glial PAR activation might account 324 
for some of the calcium responses observed in our cultures.  325 
Translating cellular signaling of sensory neurons into nociceptive response in vivo is 326 
complex, and the study of calcium signaling in primary afferents cannot fully reflect pain 327 
pathway activation.  We found no correlation between pain severity scores and pain 328 
frequency scores with the percentage of responding neurons or with the amplitude of the 329 
response to IBS tissue supernatants. This could be due to the low number of samples we 330 
included in this study considering the precious nature of human DRG neuron cultures. 331 
Indeed, other animal studies suggest that calcium signals in sensory neurons are often 332 
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 12
neurons reflected the sensitization of neurons associated to visceral hypersensitivity [12]. 334 
However, in rodents, while PAR1 agonists mobilized calcium in primary afferents [21], they 335 
also increased nociceptive threshold and reduced inflammatory hyperalgesia [4; 32]. In the 336 
present study, we showed that PAR1 specific activation mobilized calcium in human sensory 337 
neurons. The pro-nociceptive nature of this PAR1 signal is supported by our subsequent 338 
observations demonstrating the involvement of PAR1 activation in IBS patient biopsy 339 
supernatants-induced activation of human sensory neurons. Interestingly, in human 340 
submucosal and myenteric plexi, PAR1-AP (TFLLR), thrombin or supernatants of colonic 341 
biopsies from IBS patients were also able to induce spike discharges and calcium signaling. 342 
This reflected enteric neuronal excitability [29; 34]. This suggests that in humans, PAR1 might 343 
be functional both in submucosal and myenteric neurons, as well as in primary afferents (per 344 
our results). In the context of IBS, this means that PAR1 could contribute as our results 345 
suggested, to hyperexcitability of extrinsic sensory neurons leading to visceral 346 
hypersensitivity symptoms, but could also contribute to motor and secretory dysfunctions 347 
controlled by intrinsic enteric neurons. However, one has to be careful establishing a link 348 
between primary afferent response and activation of pain pathways, as in rodents, PAR1 can 349 
be activated in primary afferents, but was shown to be analgesic. Therefore, the pro-350 
nociceptive effects of PAR1 agonists remain to be demonstrated in humans. Our study paves 351 
the way for studying in human clinical trials the potential that PAR1 antagonists already 352 
developed for use in human could have at reducing pain and hyperalgesia.  353 
In agreement with the results previously generated in mouse primary afferents [6; 354 
28], we observed in human neurons as well, that PAR4-AP did not mobilize calcium, but 355 
significantly reduced calcium mobilization of stimulated sensory neurons. Here, we 356 
demonstrated for the first time an inhibitory effect for PAR4 activation on human sensory 357 
pathways, suggesting that like in rodents [5; 6], PAR4 activation could contribute at reducing 358 
pain and hypersensitivity. Taken together, our results highlight opposite effects for PAR1 and 359 
PAR4 activation in human primary sensory afferents. Considering that both receptors are 360 
activated by thrombin, although at different concentrations, it was important to investigate 361 
the overall effect of thrombin on human primary neuron calcium signaling. Thrombin is 362 
attracted to PAR1 by a Hirudin-like site located at the N-terminal end of the receptor [56]. 363 
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concentrations of thrombin for its activation (0.1 to 1u/ml). In contrast, PAR4 has no hirudin-365 
like site and higher concentrations of thrombin are requested to activate PAR4 (10u/ml) [36]. 366 
We deliberately used a concentration of thrombin that would activate both PAR1 and PAR4 367 
and observed that thrombin induced a PAR1-dependent calcium mobilization in human 368 
primary afferents (Figure 4 a,b). We also observed that the amplitude of the thrombin 369 
response in human sensory neurons was reduced by concomitant PAR4 activation. Indeed, 370 
PAR4 blockade enhanced the amplitude of thrombin-induced calcium response (Figure 4c). In 371 
keeping with these functional results, our single cell PCR data show that a population of 372 
human DRG neurons expressing PAR1 also expresses PAR4. Interestingly, PAR4 was strongly 373 
expressed in human DRG neurons. The magnitude of PAR4 effect on PAR1- or thrombin-374 
induced calcium signals in primary afferents was not as strong as it could have been 375 
expected considering the strong PAR4 expression. In primary afferents, PAR4 might have 376 
other function than counteracting the PAR1-induced signals. 377 
In contrast to studies reporting calcium mobilization in rodent sensory neurons after 378 
stimulation with PAR2-APs, or in other human cell lines [37; 54], we observed that human 379 
sensory neurons did not mobilize calcium after exposure to PAR2-APs. Interestingly, PAR2 380 
expression in human sensory DRG neurons was clearly demonstrated both at the mRNA and 381 
protein levels (Figures 1 and 2). This result was quite surprising since numerous studies have 382 
demonstrated that human cells expressing PAR2, mobilize calcium after exposure to PAR2 383 
tethered ligand synthetic peptide [39]. The lack of calcium mobilization in human sensory 384 
neurons exposed to PAR2 synthetic agonist does not mean that the receptor is silent or non-385 
functional. Indeed, other signaling pathways that have been previously described for PAR2, 386 
such as pERK or cAMP signaling might be implicated in human sensory neurons. Such 387 
pathways would have to be investigated in future studies. Furthermore, in human 388 
submucosal neurons, PAR2-AP induces very weak calcium mobilization [34], while PAR2 has 389 
been shown to be functional and potently activated by the Trypsin-3 protease in the same 390 
neurons [43]. This suggests that depending on the type of agonists that are tested (synthetic 391 
peptides or proteases), the cell response might be diverse and more or less potent. Similar 392 
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One crucial step in studying the relevance of PARs as therapeutic targets is the 395 
definition of protease profile and activities associated with pathological states. Indeed, the 396 
opposite roles for PAR1 and PAR4 we have defined here in human primary afferent signaling, 397 
suggest that depending on the proteases present and their concentration, pro- or anti-398 
nociceptive signals could be prominent. Thrombin can activate both PAR1 and PAR4, but as 399 
mentioned above, at different concentrations. Therefore, the concentration of active 400 
thrombin detected in colonic tissues from IBS patients could give an important indication on 401 
the activation status of PARs and the overall nociceptive signals. Cathepsin G activates PAR4 402 
[44], and disarms PAR1 [41]. Here again, the presence of cathepsin G in tissues could modify 403 
nociceptive status and accordingly participate to pain relief. Thus, it is clear that protease 404 
profiling will be an important step towards our comprehension of nociceptive signaling to 405 
primary afferents. However, the results presented here clearly defined that PAR1 activation 406 
on sensory neurons is involved in sensory response to mediators associated with IBS in 407 
humans, even though the proteases responsible for PAR1 activation are not yet defined. 408 
Whether PAR1 activation can potentiate transient receptor potential channels as it was 409 
demonstrated in rodent sensory neurons both for PAR1 [48] and PAR2 [2; 3; 15; 16; 18; 24] 410 
would still have to be confirmed in human primary afferents.  411 
One major limitation of the present study though is that even if we have harvested 412 
thoracic DRGs containing neurons projecting from the colon, not all neurons present in the 413 
culture dishes are colonic projections. We cannot define whether colonic projections are 414 
responding to supernatants of IBS patients, or even whether colonic projections are indeed 415 
expressing the different PARs. In animal studies, retrograde labeling of projecting neurons is 416 
used to identify the origin of the neurons, but this is hardly applicable to human studies. 417 
In conclusion, this study describes in human sensory neurons, the expression of PARs 418 
and their ability to generate calcium signaling. The results highlight the functionality of PAR1 419 
as an activator of calcium-dependent signaling and PAR4 as an inhibitor of such signaling. 420 
Most importantly, mediators from IBS patient tissues signal to human primary afferent in a 421 
PAR1-dependent mechanism, illustrating the potential of PAR1 antagonism as a new 422 
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Figure legends 610 
Figure 1: Expression of PARs in whole human DRG. (a) Relative expression of PAR1 611 
(white bar), PAR2 (gray bar) and PAR4 (black bar) mRNA in human DRG normalized with 612 
GAPDH expression; n=5 human DRG from 5 different donors. (b) Representative pictures of 613 
PAR1 (blue), PAR2 (red), PAR4 (green) and PGP9.5 (white, arrows = neurons, arrow heads = 614 
nerves fibers) immunodetection on slices of human DRG; scale bar = 50 µm. (c) Percentage 615 
of PAR expression on PGP9.5 positive cells in slice of T11 and T12 DRG from 3 donors. 616 
For PAR1 expression 154 neurons were counted, 162 for PAR2 and 89 for PAR4. (d) 617 
Percentage of PAR–immunoreactive neurons according to the diameter of neuronal perikarya. 618 
(c), (d), n = 3 x (T11 + T12). For each condition, a  average of the percentage obtained on 3 619 
pictures was performed. 620 
 621 
Figure 2: Expression of PARs in cultured human DRG neurons. 622 
(a) Expression of PAR1 (in white), PAR2 (in gray) and PAR4 (in black) mRNA transcripts by 623 
single-cell RT-qPCR (left panel) of human neurons (TUBB3 positive cells). Pie charts 624 
representation of the expression (dark color) or not (light color) of PAR1 (in blue), PAR2 (in 625 
red) and PAR4 (in green) mRNA in human neurons (right panel). Each segment represents a 626 
single neuron. n = 26 neurons. (b) Representative pictures of PARs (in red) and PGP9.5 (in 627 
green) immunodetection in cultures of human DRG; scale bar = 50 µm. (c) Percentage of 628 
PAR expression on PGP9.5-positive cells in human DRG neuron cultures from 5 different 629 
donors. Two wells for each condition were counted:112 neurons for PAR1 labelling, 134 for 630 
PAR2 and 88 for PAR4 were counted. 631 
 632 
Figure 3: Effects of PAR-AP in human sensory neurons.  633 
(a) Representative trace of calcium flux experiment obtained in one well of human sensory 634 
neuron culture exposed to PAR1-AP, PAR2-AP or PAR4-AP (100 µM each). Percentage of 635 
responding neurons (b) and amplitude of intracellular calcium mobilization (∆F/F; c) in 636 
human sensory neurons exposed to PAR agonist peptides (PAR-AP, 100 µM, black bar) or 637 
inactive peptides (PAR-IP, 100 µM, white bar). n=6 to 8 independent experiments of 3 wells 638 
per condition and 20-53 neurons per well.  (d) Calcium flux amplitude of responding neurons 639 
exposed to PAR1-IP (100 µM, white bar) or to increasing doses of PAR1-AP (1, 10, 50 and 640 
100 µM, black bar) pretreated or not with a PAR1 antagonist (SCH79797, 10µM). n=4 to 5 641 
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Representative trace of calcium flux experiment obtained in one well of human sensory 643 
neurons culture exposed to PAR1-AP (100 µM) and pre-incubated with PAR2-AP or PAR4-644 
AP (100 µM each). Percentage of responding neurons (f) and amplitude of intracellular 645 
calcium mobilization (∆F/F; g) in human sensory neurons exposed to PAR1- P (100 µM, all 646 
bars) and pretreated with PAR2-IP or PAR4-IP (100 µM, white bar), PAR2-AP (100 µM, gray 647 
bar) or PAR4-AP (100µM, black bar). n=3 to 4 independent experim nts of 3 wells per 648 
condition and 30-58 neurons per well. Statistical analysis was performed using Kruskal-649 
Wallis analysis of variance and subsequent Dunn’s post hoc test. * p<0.05, ** p<0.01, *** 650 
p<0.001, significantly different from the corresponding inactive-peptide groups; £££ p < 651 
0.001, significantly different from PAR1-AP (100µM). 652 
 653 
Figure 4: Effects of thrombin in human DRG neurons. 654 
Percentage of responding neurons (a) and amplitude of intracellular calcium mobilization 655 
(∆F/F; b) in human DRG neurons exposed to thrombin (10 U/mL, black bar) or its vehicle 656 
(HBSS, white bar). n=3 to 4 independent experiments of 3 wells per condition and 31-45 657 
neurons per well. Statistical analysis was performed using Mann-Whitney test. * p<0.05, ** 658 
p<0.01, significantly different from HBSS group. Perc ntage of responding neurons (c) and 659 
amplitude of intracellular calcium mobilization (∆F/F; d) in human sensory neurons exposed 660 
to thrombin (10 U/mL, all bars) and pretreated with PAR1 antagonist (SCH79797, 10 µM, 661 
gray bar), PAR4 antagonist (ML354, 10 µM, black bar) or their vehicle (HBSS, white bar). 662 
n=3 independent experiments of 3 wells per condition and 39-68 neurons per well. Statistical 663 
analysis was performed using Kruskal-Wallis analysis of variance and subsequent Dunn’s 664 
post hoc test. * p<0.05, *** p<0.001, significantly different from the corresponding inactive-665 
peptide groups. 666 
Figure 5: Effects of supernatants from colonic biopsies of IBS patients or healthy 667 
controls on calcium mobilization in human DRG neurons.  668 
(a) Representative trace of calcium flux experiment obtained in one well of human sensory 669 
neuron culture exposed to supernatant of diarrhea-pr dominant IBS patient (hexagon) or to 670 
healthy control (HC, circle). Amplitude of intracellular calcium mobilization (∆F/F; b) in 671 
human sensory neurons and percentage of responding eurons (c) exposed to supernatants 672 
from colonic biopsies of IBS patients: constipation-predominant (-C, triangle), diarrhea-673 
predominant (-D, hexagon), alternate (-A, square) o to supernatants from colonic biopsies of 674 
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one well of human sensory neurons culture exposed to supernatant of alternate-predominant 676 
IBS patient (square) and pretreated with PAR1 antagonist (SCH79797, 10 µM, gray square) or 677 
its vehicle (white square). Amplitude of intracellular calcium mobilization (∆F/F; e) in human 678 
sensory neurons and percentage of responding neurons (f) exposed to supernatants from 679 
colonic biopsies of IBS patients: constipation-predominant (-C, triangle), diarrhea-680 
predominant (-D, hexagon) or alternate (-A, square) nd pretreated with PAR1 antagonist 681 
(SCH79797, 10 µM), or its vehicle. Data are represented as scattered dot plot with line at 682 
mean. Each symbol represents one patient. n=6 indepe nt experiments of 3 wells per 683 
condition and 42-53 neurons per well. Statistical analysis was performed using Mann-684 
Whitney test (b and c) or Wilcoxon matched pairs test (e and f). * p<0.05, ** p<0.01, 685 
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